key: cord-0888007-879d3f3j
authors: Zein, Ahmad Fariz Malvi Zamzam; Raffaello, Wilson Matthew
title: Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 – A systematic review and meta-analysis
date: 2021-12-13
journal: Prim Care Diabetes
DOI: 10.1016/j.pcd.2021.12.008
sha: 2a4fa314d261a40ab600d80481f12b5086a07391
doc_id: 888007
cord_uid: 879d3f3j

INTRODUCTION: This systematic review and meta-analysis aimed to synthesize the latest evidence on the effect of dipeptidyl peptidase-4 (DPP-IV) inhibitor in patients with COVID-19. METHODS: We performed a systematic literature search from the PubMed, Scopus, Embase, and Clinicaltrials.gov up until 15 July 2021. Studies that met the following criteria were included: prospective or retrospective observational studies or case series or randomized controlled trials (RCTs) reporting DPP-IV inhibitor use in patients with COVID-19 and mortality. The intervention group was patients receiving DPP-IV inhibitor. The control group was patients that did not receive DPP-IV inhibitor. The outcome was mortality reported as odds ratio (OR). RESULTS: There were 11 studies consisting of 5,950 patients in this meta-analysis. DPP-IV inhibitor use was associated with reduced mortality (OR 0.75 [0.56, 0.99], p = 0.043, I(2): 42.9, p = 0.064) compared to those that did not receive DPP-IV inhibitor. Sensitivity analysis using the fixed-effect model (OR 0.75 [0.63, 0.88], p < 0.001, I(2): 42.9, p = 0.064) also showed mortality benefit. The association between DPP-IV inhibitor and mortality was not significantly affected by age (p = 0.540), sex (p = 0.054), hypertension (p = 0.320), location (continent; p = 0.532), and retrospective/prospective nature of the study (p = 0.840). However, the association was affected by metformin (OR 1.03 [95% CI 1.01, 1.06], p = 0.010) and ACEI/ARB use (OR 1.06 [95% CI 1.02, 1.10], p = 0.004). CONCLUSION: This meta-analysis showed that DPP-IV inhibitor was associated with reduced mortality in patients with COVID-19.

COVID-19 caused mortality either directly through biological mechanism or indirectly by disrupting health care system. [1] [2] [3] [4] [5] [6] Type 2 diabetes mellitus (T2DM) is a common comorbidity in patients with COVID-19 and also is well known as a risk factor for developing a more severe condition in COVID- 19 5,7-9 . Whether the glucose lowering agents that are commonly used among T2DM patients affect the outcome of the COVID-19 patients is important. The most important goal is to establish the evidence on whether these medications are harmful, neutral, or beneficial in patients with COVID-19. It is then found that antidiabetic medications may actually improve the outcome, especially by improving cardiovascular and renal function which is commonly impaired during the course of infection 10-12 . Previously, metformin was found to be beneficial in patients with COVID-19 13 . One particular antidiabetic medication that has recently raised considerable interest is the relatively new dipeptidyl peptidase-4 (DPP-IV) inhibitor, which is well known for its excellent safety profile 14 and widely used as a treatment of T2DM. The use of DPP-IV inhibitor raises some concern due to its role in the regulation of T-cell activity, however, studies shown that DPP-IV inhibitor might be beneficial in patients with COVID-19. Nevertheless, although several studies showed potential benefit, the other studies showed null effect on the mortality in patients with COVID-19. This systematic review and meta-analysis aimed to synthesize the latest evidence on the effect of DPP-IV inhibitor in patients with COVID-19.

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Metaanalysis (PRISMA) guideline.

We performed a systematic literature search from the PubMed, Scopus, Embase, and Clinicaltrials.gov for "(SARS-CoV-2 OR 2019-nCoV OR COVID-19) AND (dipeptidyl peptidase-4 OR DPP-4 OR DPP-IV)" from the beginning of time until 15 July 2021. Two independent authors performed title/abstract screening and eligibility assessment of the articles. Discrepancies were resolved by discussion.

Studies that met the following criteria were included: prospective or retrospective observational studies or case series or randomized controlled trials (RCTs) reporting DPP-IV inhibitor use in patients with COVID-19 and mortality.

Studies that met one of the following criteria were excluded: 1) review articles, 2) editorial/commentaries, 3) abstracts, 4) letters, and 5) case reports. Language restriction was not imposed.

The intervention group was patients receiving DPP-IV inhibitor. The control group was patients that did not receive DPP-IV inhibitor. The outcome was mortality. The effect estimate was reported as odds ratio (OR).

Two independent authors performed data extraction of the eligible studies using standardized extraction form for the first author, study design, location of the study, inclusion criteria, sample size, age, sex, comorbidities, medication use, and the mortality in the intervention and control groups. Discrepancies during data extraction were resolved by discussion.

Two independent authors performed risk of bias assessment using the Newcastle-Ottawa Scale (NOS) 15 . Discrepancies during risk of bias assessment were resolved by discussion.

Random-effects meta-analysis using the Der-Simonian Laird statistical method was performed to pool the effect of DPP-IV inhibitor on mortality. Random-effects model was used regardless of heterogeneity and fixed-effects model was performed in sensitivity analysis. P-values of ≤ 0.05 indicate statistical significance. I 2 statistics were used to inter-study heterogeneity, in which a value above 50% or p-value < 0.10 indicates substantial heterogeneity. Random-effects restricted maximum likelihood (REML) meta-regression analysis was performed to evaluate the effect of study design, location, comorbidities, and medication on the association between DPP-IV inhibitor and mortality. Statistical analysis was performed using STATA version 16.0.

There were 11 studies consisting of 5,950 patients in this meta-analysis [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The selection process is described in PRISMA flowchart as illustrated in [ Figure 1 ]. Characteristics of the included studies can be seen in Table 1 . There were 7 retrospective observational studies, 3 prospective observational studies, and 1 case series. 7 studies were conducted in Europe, 3 in Asia, and 1 in North America. showed mortality benefit.

The association between DPP-IV inhibitor and mortality was not significantly affected by age (p=0.540), sex (p=0.054), hypertension (p=0.320), location (continent; p=0.532), and retrospective/prospective nature of the study (p=0.840). However, the association was affected by 

The risk of bias assessment using NOS can be seen in Table 1 . Funnel-plot was symmetrical [ Figure 4 ] and there was no indication of small-study effects (p=0.823).

This meta-analysis showed that the risk of mortality was lower in COVID-19 patients receiving DPP-IV inhibitor. Meta-regression analysis indicate that the results do not vary with age, sex, hypertension, the location of the study, and retrospective/prospective nature of the studies.

However, the benefit of DPP-IV inhibitor is less pronounced in patients that receive metformin and ACEI/ARB. Metformin is often regarded as first-line antidiabetic medication and ACEI/ARB is often prescribed in patients with concurrent hypertension, cardiovascular diseases, and renal damage. Both metformin and ACEI/ARB have been shown to be associated with better prognosis in patients with COVID-19 13, 34, 35 , thus, the proportion of benefit from DPP-IV inhibitor may be lower when combined with other medications that may improve prognosis.

Comorbidities are important to be analyzed in meta-regression because they are associated with poor outcome in patients with COVID-19 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . One of the study was excluded because the outcome was composite of mortality and intensive care unit admission, there was no separate data on mortality, the study showed that DPP-IV inhibitor was associated with better clinical outcome 51 .

J o u r n a l P r e -p r o o f DPP-IV inhibitor is originally known as T-cell antigen CD26, is a cell receptor which is abundantly expressed in various cells such as lymphocyte, adipocyte, endothelial, lung epithelium, and also on the surface of various immune cells and regulates their function 52, 53 . DPP-IV, which is closely linked to the cardiovascular biology, also plays an important role in regulating the inflammatory and immune response as it has the capability to modulate various cytokine, chemokine, peptide hormones 54, 55 . Therefore, the use of DPP-IV inhibitor raises some concern over increasing susceptibility to infections, given the role of DPP-IV inhibitor in the regulation of T-cell activity poor glucose control, cytokine storm, and multiorgan dysfunction have been established as a risk factor for worse outcome 40, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] , one might consider the benefit of excellent glucose control, cardiorenal effect and inflammatory modulation of DPP-IV inhibitor as an potential drug in treating T2DM patient with COVID-19 5, 75 .

This study includes several observational studies with various populations and regions. There were 7 studies conducted in Europe, 3 in Asia, and 1 in North America. The limitation of this meta-analysis is that most of the studies were retrospective observational, RCTs are required to establish a more certain evidence. Many studies did not adequately report medications used by the patients, as shown in meta-regression analysis, medications may significantly affect the benefit of DPP-IV inhibitor in patients with COVID-19. There are other medications that were not adequately reported by most of the studies that may affect prognosis in patients with diabetes and COVID-19 76, 77 .

This meta-analysis showed that DPP-IV inhibitor was associated with reduced mortality in patients with COVID-19 and results do not vary with age, sex, hypertension, the location of the study, and retrospective/prospective nature of the studies. However, further study with RCT added to the analysis is needed to establish a more certain evidence.

None J o u r n a l P r e -p r o o f

Data are available on reasonable request Figures: 4 Table: 1

Contributorship Statement: AFMZZ was involved in the conceptualization and design of the manuscript. AFMZZ and WMR participated in data curation and investigation. AFMZZ performed formal and statistical analysis. AFMZZ and WMR drafted the manuscript. AFMZZ and WMR review and edited the manuscript. 

Coronavirus disease 2019 (COVID-19) markedly increased mortality in patients with hip fracture -A systematic review and meta-analysis

Impact of the Coronavirus Disease Pandemic on the Number of Strokes prognosis during the COVID-19 pandemic

Worrying situation regarding the use of dexamethasone for COVID

Diabetes and COVID-19: The past, the present, and the future

A time-to-event analysis on air pollutants with the risk of cardiovascular disease and mortality: A systematic review and meta-analysis of 84 cohort studies

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Patients with diabetes are at higher risk for severe illness from COVID-19

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression: Diabetes and COVID-19

Potential benefits and harms of drugs during COVID-19 crisis

Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection

The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis

The safety of gliptins : updated data

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ottawa Hosp Res Inst

Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study

Exposure to dipeptidyl-peptidase-4 inhibitors and

COVID-19 among people with type 2 diabetes: A case-control study

Predictors of severe COVID-19 disease in patients with diabetes: a multi-center review

Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily

Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication

Association between dpp-4 inhibitors and covid-19-related outcomes among patients with type 2 diabetes

Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with covid-19: A case series from an academic hospital in lombardy, italy. Diabetes Care

Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: A multicenter case-control retrospective observational study

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies

DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) -A systematic review, meta-analysis, and meta-regression

Original research: Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong

Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study. Diabetes

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression

Low Serum 25-hydroxyvitamin D

Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis. Front Nutr

Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis

The Danger of Sedentary Lifestyle in Diabetic and Obese People During the COVID-19 Pandemic

Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-J o u r n a l P r e -p r o o f analysis, and meta-regression

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis

Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression

Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta-analysis

Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis: Clinical Frailty Scale in COVID-19

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

Visceral adiposity, subcutaneous adiposity, and severe -2019 (COVID-19): Systematic review and meta-analysis

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

The biology of incretin hormones

Cardiovascular biology of the incretin system

Cardiovascular effects of gliptins

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. iScience

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Elevated interleukin levels are associated with higher severity and mortality in COVID 19 -A systematic review, meta-analysis, and metaregression

Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression

Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: A systematic review and meta-analysis

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Fibrosis-4 index and mortality in coronavirus disease 2019

Repurposing FIB-4 index as a predictor of mortality in patients with hematological malignancies and COVID-19

Effect of heart failure on the outcome of COVID-19 -A meta analysis and systematic review

Left and right ventricular longitudinal strains are associated with poor outcome in COVID-19: a systematic review and meta-analysis

Thrombocytopenia as a prognostic marker in COVID-19 patients: Diagnostic test accuracy meta-analysis

Endotheliopathy Marked by High von Willebrand Factor (vWF) Antigen in COVID-19 is Associated with Poor Outcome: A Systematic Review and Meta-analysis

Delirium and Mortality in Coronavirus Disease 2019 (COVID-19) -A Systematic Review and Meta-analysis

Elevated N-Terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: Systematic review and meta-Analysis

Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: A systematic review and meta-analysis

Prognostic value of fasting hyperglycemia in patients with COVID-19 -Diagnostic test accuracy meta-analysis

Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates

Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts